CSIMarket Company Name, Ticker, Competitors, else..
 
Comera Life Sciences Holdings Inc   (NASDAQ: CMRA)
Other Ticker:  
 
 
Price: $0.0002 $0.00 -33.333%
Day's High: $0.0002 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: -99.2 %
Volume (M): 60 52 Wk High: $ 0.09
Volume (M$): $ 0 52 Wk Avg: $0.04
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 23
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Comera Life Sciences Holdings Inc
Comera Life Sciences Holdings Inc is a company that operates in the life sciences industry. It is known for its expertise in research and development, as well as the manufacturing and commercialization of products in the healthcare sector. The company focuses on areas such as pharmaceuticals, biotechnology, medical devices, and diagnostics. Comera Life Sciences Holdings Inc aims to enhance the quality of life for patients by developing innovative solutions and treatments for various medical conditions.


   Company Address: 12 Gill Street Woburn 1801 MA
   Company Phone Number: 871-2101   Stock Exchange / Ticker: NASDAQ CMRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -3.7%    
LLY   -3.48%    
REGN        2.15% 
TEVA   -2.58%    
VRTX        1.13% 
VTRS   -4.06%    
• View Complete Report
   



Management Announcement

Comera Life Sciences' Strategic Alternatives Process: Paving the Path Towards Biotech Innovation and Shareholder Value Maximization

Published Wed, Dec 6 2023 1:30 PM UTC

Comera Life Sciences Initiates Strategic Alternatives Process to Enhance Shareholder Value
WOBURN, Mass., Dec. 06, 2023 - Comera Life Sciences Holdings, Inc. (OTCQB: CMRA), a pioneering life sciences company dedicated to developing advanced biologic medicines to enhance patient access, safety, and convenience, has taken a significant step towards maximizing shareholder v...
Comera Life Sciences Holdings Inc

Fortunes Take a Plunge: CMRA Fights Back After Revenue Drop in Financial Period Ending Sep 30, 2023



Comera Life Sciences Holdings Inc, a major pharmaceutical preparations company, has recently reported disappointing financial results for the most recent fiscal period. The company witnessed a significant decline in revenue and a growing net deficit per share. However, amidst these setbacks, Comera Life Sciences presented research demonstrating the capabilities of its SQore platform in the development of subcutaneous monoclonal antibody formulations. It is essential to analyze the impact of their financial results and the potential implications for the company's future.
Financial Meltdown:
In the financial period ending September 30, 2022, Comera Life Sciences Holdings Inc experienced a significant decline in revenue of -41.976%, dropping to $0.14 million. This steep decline raises concerns about the company's ability to maintain a stable financial position. Additionally, the net deficit per share rose to $-0.10, reflecting a negative financial trend compared to the previous reporting period. This downward spiral from a loss of $-0.08 per share indicates a challenging financial landscape.
Comera Life Sciences Holdings Inc

Comera Life Sciences Holdings Inc achieves remarkable earnings turnaround, with loss per share plunging to just $-0.08 in Q2 2023



Comera Life Sciences Holdings Inc, a company traded on NASDAQ, has recently experienced notable gains in its share price. Over the course of the last five trading days, the company's shares recorded a solid gain of 6.56%. Furthermore, in the past 30 days, Comera's shares improved by an impressive 11.36%. However, despite these positive trends, the company's shares are currently trading 47.1% below its 52-week average. To gain a deeper understanding of Comera's financial situation, let's examine the recently reported financial results for the April to June 30, 2023 interval.
Decreased Loss per Share and Improved EPS:
During the April to June 30, 2023 interval, Comera Life Sciences Holdings Inc managed to decrease its loss per share to $-0.08 from $-1.14 compared to the same period last year. This improvement is particularly significant and demonstrates the company's efforts to enhance its financial performance. Additionally, the company's earnings per share (EPS) showed improvement, rising from $-0.13 in the prior reporting season to the current -$0.08 per share.
Comera Life Sciences Holdings Inc

Major Pharmaceutical Preparations Company Reports Revenue of $0.392915 Million, Demonstrating Stability Amidst Industry Challenges

The stock market can be a volatile and challenging place to invest, but there are always opportunities for growth and success. Despite recent challenges, Comera Life Sciences Holdings Inc may be one such opportunity worth considering.
While the company has seen a cumulative net loss of $-20 million over the last 12 months, its revenue is still relatively strong, sitting at $0.392915 million in the financial interval closing March 31, 2023. Additionally, while its return on assets (ROA) is currently negative at -460.5%, it's worth noting that 687 healthcare companies have a higher ROA.






Comera Life Sciences Holdings Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com